NASDAQ:IMRX

Immuneering Stock Insider Trading

Healthcare > Biotechnology

Buy IMRX

*Your capital is at risk

$4.13

-0.100 (-2.36%)

At Close: Jul 31, 2026

Immuneering Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.11M and sold 0 IMRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	6.11M shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 01, 2025 Buy	Class A Common Stock P-Purchase	Zeskind Benjamin J. President And CEO	CEO / President	2 985 Value: $10.1K
Jul 01, 2025 Buy	Class A Common Stock P-Purchase	Zeskind Benjamin J. President And CEO	CEO / President	2 985 Value: $10.1K
Jun 27, 2025 Buy	Class A Common Stock P-Purchase	Schall Thomas J. Director	Director	9 500 Value: $34.8K
Jun 27, 2025 Buy	Class A Common Stock P-Purchase	Schall Thomas J. Director	Director	9 500 Value: $34.8K
Jun 23, 2025 Buy	Class A Common Stock P-Purchase	Hall Brett Matthew Chief Scientific Officer	Officer	6 007 Value: $14.6K
Jun 23, 2025 Buy	Class A Common Stock P-Purchase	Hall Brett Matthew Chief Scientific Officer	Officer	6 007 Value: $14.6K
Jun 20, 2025 Buy	Class A Common Stock P-Purchase	Hall Brett Matthew Chief Scientific Officer	Officer	7 415 Value: $20.0K
Jun 20, 2025 Buy	Class A Common Stock P-Purchase	Brakewood Harold Eugene Chief Business Officer	Officer	1 900 Value: $5K
Jun 20, 2025 Buy	Class A Common Stock P-Purchase	Brakewood Harold Eugene Chief Business Officer	Officer	1 900 Value: $5K
Jun 20, 2025 Buy	Class A Common Stock P-Purchase	Hall Brett Matthew Chief Scientific Officer	Officer	7 415 Value: $20.0K
Jun 18, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	25 000 Value: $63.2K
Jun 18, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	25 000 Value: $63.2K
Jun 18, 2025 Buy	Class A Common Stock P-Purchase	Zeskind Benjamin J. President And CEO	CEO / President	21 000 Value: $50.1K
Jun 18, 2025 Buy	Class A Common Stock P-Purchase	Zeskind Benjamin J. President And CEO	CEO / President	21 000 Value: $50.1K
Jun 17, 2025 Buy	Class A Common Stock P-Purchase	Schall Thomas J. Director	Director	40 485 Value: $89.3K
Jun 17, 2025 Buy	Class A Common Stock P-Purchase	Schall Thomas J. Director	Director	40 485 Value: $89.3K
Jun 13, 2025 Buy	Stock Option A-Award	Hausman Diana Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Schall Thomas J. Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Keating Laurie Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Feinberg Peter Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Carpenter Robert J Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Berman Ann E Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Berman Ann E Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Carpenter Robert J Director	Director	33 350 Value: $63.4K
Jun 13, 2025 Buy	Stock Option A-Award	Feinberg Peter Director	Director	33 350 Value: $63.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNEERING CORPORATION

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed ...

Read Full Profile Here